ELI LILLY AND COMPANY Inventory, Raw Materials, Gross
ELI LILLY AND COMPANY (LLY) had Inventory, Raw Materials, Gross of $4.13 billion as of 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Notes › Inventory › Inventory, Gross
us-gaap:InventoryRawMaterials · last filed 2026-08-05
- 2026-06-30: Inventory, Raw Materials, Gross $4.13B.
- 2026-03-31: Inventory, Raw Materials, Gross $3.76B.
- 2025-12-31: Inventory, Raw Materials, Gross $3.59B.
- 2025-09-30: Inventory, Raw Materials, Gross $3.40B.
| Period end | Inventory, Raw Materials, Gross | Inventory, Raw Materials, Gross as first filed |
|---|---|---|
| 2026-06-30 | $4.13B 10-Q · filed 2026-08-05 | |
| 2026-03-31 | $3.76B 10-Q · filed 2026-04-30 | |
| 2025-12-31 | $3.59B 10-Q · filed 2026-08-05 | |
| 2025-09-30 | $3.40B 10-Q · filed 2025-10-30 | |
| 2025-06-30 | $3.15B 10-Q · filed 2025-08-07 | |
| 2025-03-31 | $2.69B 10-Q · filed 2025-05-01 | |
| 2024-12-31 | $2.33B 10-K · filed 2026-02-12 | |
| 2024-09-30 | $2.24B 10-Q · filed 2024-10-30 | |
| 2024-06-30 | $1.88B 10-Q · filed 2024-08-08 | |
| 2024-03-31 | $1.69B 10-Q · filed 2024-04-30 | |
| 2023-12-31 | $1.63B 10-K · filed 2025-02-19 | |
| 2022-12-31 | $801.90M 10-K · filed 2024-02-21 | |
| 2021-12-31 | $717.20M 10-K · filed 2023-02-22 | |
| 2020-12-31 | $651.20M 10-K · filed 2022-02-23 | |
| 2019-12-31 | $424.60M 10-K · filed 2021-02-17 | |
| 2018-12-31 | $426.10M 10-K · filed 2020-02-19 | $506.50M 10-K · filed 2019-02-19 |
| 2017-12-31 | $418.40M 8-K · filed 2019-10-24 | $488.80M 10-K · filed 2018-02-20 |
| 2016-12-31 | $435.30M 10-K · filed 2018-02-20 | |
| 2015-12-31 | $403.00M 10-K · filed 2017-02-21 | |
| 2014-12-31 | $315.00M 10-K · filed 2016-02-19 | |
| 2013-12-31 | $259.00M 10-K · filed 2015-02-19 | |
| 2012-12-31 | $256.10M 10-K · filed 2014-02-19 | |
| 2011-12-31 | $205.80M 10-K · filed 2013-02-21 | |
| 2010-12-31 | $220.80M 10-K · filed 2012-02-24 | |
| 2009-12-31 | $227.80M 10-K · filed 2011-02-22 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Akari Therapeutics Plc (AKTX) | $1,527.991B | -47,921.42 | |
| JOHNSON & JOHNSON (JNJ) | United States | $652.528B | 29.10 |
| AbbVie Inc. (ABBV) | United States | $468.180B | 70.37 |
| Merck & Co., Inc. (MRK) | United States | $365.215B | 99.96 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |